Glenolden, Pa. (PRWEB) July 25, 2012
The Charcot-Marie-Tooth Association, a national non-profit devoted to Charcot-Marie-Tooth (CMT) disorder, is pleased to announce a partnership with Aetrex Worldwide, Inc., a global leader in comfort and wellness footwear products based in Teaneck, New Jersey. The partnership will focus on two critical areas; the delivery of comfortable, well-designed shoe solutions to people with CMT while creating awareness about CMT and the CMTA to the public and the trade through Aetrex’s broad reach of customers and professionals.
“The footwear options provided by Aetrex are a natural fit for those with CMT,” said Pat Livney, CEO of the Charcot-Marie-Tooth Association. “The multiple shoe lines offered by Aetrex provide numerous solutions for those who usually have difficulty finding a comfortable and stylish shoe. The CMTA is grateful to provide opportunities to improve the quality of life for CMT patients across the country. This partnership will definitely fill the basic need of quality, well-fitted shoes.”
An estimated one in every 2,500 people – 2.6 million worldwide – has CMT. It is a progressive disorder that causes the nerve cells leading to the body’s extremities to slowly degenerate, resulting in the loss of normal use of the hands/arms and legs/feet. It may also lead to a loss of sensory functions and structural changes in the feet and hands, which can lead to difficulties finding shoes that fit correctly. CMT affects people of all ages, genders, races and ethnicities, yet sometimes is overlooked and not routinely diagnosed in patients.
Founded in 1946, Aetrex Worldwide, Inc. is widely recognized as the global leader in pedorthic footwear and foot orthotics. Aetrex is a family business which has pioneered innovations in pain-relieving footwear and footcare products. Originally known for the development of custom orthotics, medically oriented footcare products and innovations in over-the-counter insoles, Aetrex now offers attractive shoes in their product line that feature extra depth or width to accommodate in-shoe orthotics or AFOs to appeal to a broad database of customers. Aetrex publishes two weekly e-newsletters, Footprints delivered weekly to their customers and Pedorthic Newswire, delivered to over 5,000 subscribing industry professionals such as pedorthists and orthotists.
“We’re very excited to partner with the CMTA,” said Larry Schwartz, CEO of Aetrex. “Their vision of seeing a world without CMT is something we hope to help them accomplish.”
Together the CMTA and Aetrex Worldwide, Inc. will increase awareness about CMT while meeting the fundamental but unmet need of a well-fit shoe for those living with CMT. For more information, please visit http://www.cmtausa.org.
About the Charcot-Marie-Tooth Association (CMTA):
The CMTA, headquartered in Pennsylvania, is a 501(c)3 nonprofit organization founded in 1983. The CMTA’s goals include providing patient support, public education, promotion of research, and ultimately the improved treatment and cure of CMT. Scientific and technological advances have enabled the Association to implement an initiative, known as the Strategy to Accelerate Research™ (STAR), which is designed to lead to new treatments for Charcot-Marie-Tooth disorder (CMT) within three to five years and possibly to a cure within ten years.
About Aetrex Worldwide, Inc.:
Aetrex Worldwide, with over 20 Certified Pedorthists on staff, is the industry leader in pedorthic footwear, the leading manufacturer of mid-priced orthotics and the number one provider of foot scanning and measuring technology for retailers and the medical community. The $65-million dollar corporation, founded in 1946 and privately owned by the Schwartz family for three generations, is comprised of three divisions -- Aetrex Performance Products, Aetrex Technology & Orthotics, and Apex Therapeutic Footcare. For additional information, visit http://www.aetrex.com.